Eltrog 25MG Tablet (7’s) is a medication that contains Eltrombopag as its active ingredient, with each tablet delivering a dosage of 25 mg. This drug is primarily used to treat conditions related to low platelet counts, such as chronic immune thrombocytopenic purpura (ITP) in adults and children, as well as thrombocytopenia associated with chronic hepatitis C and severe aplastic anemia. Eltrombopag works by stimulating the production of platelets in the bone marrow, thereby increasing platelet counts and reducing the risk of bleeding. The formulation of Eltrog 25MG Tablet is designed for oral administration, making it convenient for patients. It is essential for individuals with low platelet counts to manage their condition effectively, and Eltrog provides a viable option for improving their health outcomes. The medication is typically prescribed as part of a comprehensive treatment plan, and patients should follow their healthcare provider’s instructions for optimal results.

Revolade 25MG Tablet, containing Eltrombopag as its active ingredient, is a medication primarily used to treat certain blood disorders, particularly thrombocytopenia, which is characterized by low platelet counts. This condition can arise from various causes, including chronic immune thrombocytopenic purpura (ITP) and hepatitis C virus (HCV) infection. Each tablet contains 25 mg of Eltrombopag, which works by stimulating the production of platelets in the bone marrow. Revolade is available in a pack of seven tablets, making it convenient for patients to manage their treatment regimen. The drug is designed to improve platelet counts, thereby reducing the risk of bleeding and other complications associated with low platelet levels. As a thrombopoietin receptor agonist, Revolade plays a crucial role in enhancing the body’s natural ability to produce platelets, making it an essential option for patients suffering from conditions that lead to thrombocytopenia.